After the chaos of 2020 and 2021, 2022 showed hints of a return to normalcy. But what might 2023 bring? Executives from Edwards, Medtronic, Qiagen and more shared their predictions for the year ahead.
Peter Arduini
What's ahead for device companies in 2023? In this year-end special feature, execs at top device companies and other stakeholders share what they expect.
After the chaos of 2020 and 2021, 2022 showed hints of a return to normalcy. But what might 2023 bring? Executives from Edwards, Medtronic, Qiagen and more shared their predictions for the year ahead.
Peter Arduini
In this week's Digital Health Roundup, Medtech Insight's team discusses progress on autonomous surgery, Medtronic's new partnership with IRCAD, FDA cybersecurity news, and C-suite interviews with OpenWater, Flow Neuroscience and EnsoData.
A recent FDA warning letter claims a Boston firm that specializes in wearable technology marketed a blood pressure device without agency approval. The company rejects the assertion and says the agency is out of step with federal law.
US Medicare has proposed national coverage of renal denervation for patients with uncontrolled hypertension. The treatment is seeing other advances as well, with Medtronic piloting a longer catheter and a multi-organ approach and a blood test to identify the best candidates fresh on the